文献速递乳腺癌

乳腺癌新辅助化疗后病理完全缓解能否通过微创活检诊断?

Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
PubMed 文献 · Eur J Cancer · 2016-11-04

本研究在50例乳腺癌患者新辅助化疗后、手术前进行超声引导下真空辅助微创活检(VAB),评估其诊断病理完全缓解(pCR,即ypT0)的能力。总体队列中VAB的阴性预测值为76.7%、假阴性率为25.9%;在组织病理学评估为代表性样本的38例中,阴性预测值为94.4%(95%CI 87.1-100.0)、假阴性率为4.8%(95%CI 0.0-11.6)。结论认为,在组织病理学代表性样本前提下,VAB可准确诊断pCR。

要点

  • 总体队列VAB诊断pCR的阴性预测值为76.7%,假阴性率为25.9%。
  • 组织病理学代表性样本中阴性预测值为94.4%(95%CI 87.1-100.0)。
  • 组织病理学代表性样本中假阴性率为4.8%(95%CI 0.0-11.6)。

核心结论

  • 在组织病理学代表性样本前提下,VAB可准确诊断乳腺癌新辅助化疗后的病理完全缓解(pCR)。

研究设计与样本

  • 研究在50例乳腺癌患者新辅助化疗后、乳腺手术前进行超声引导下真空辅助微创活检(VAB),以手术标本预测pCR的阴性预测值和假阴性率为主要结局指标。

主要发现

  • 队列(n=50)包括15例(30%)三阴性乳腺癌、13例(26%)人表皮生长因子受体2(HER2)阳性乳腺癌和22例(44%)激素受体阳性/HER2阴性乳腺癌。
  • 23例(46%)诊断为ypT0。
  • 总体队列(n=50)中VAB的阴性预测值为76.7%,假阴性率为25.9%。
  • 按组织病理学评估为代表性VAB样本者(n=38),阴性预测值为94.4%(95%CI 87.1-100.0),假阴性率为4.8%(95%CI 0.0-11.6)。
  • 非代表性VAB主要因超声下目标病灶可见性差所致。

关键数值与推荐

  • 总体队列(n=50):VAB预测pCR的阴性预测值76.7%,假阴性率25.9%。
  • 组织病理学代表性样本(n=38):阴性预测值94.4%(95%CI 87.1-100.0),假阴性率4.8%(95%CI 0.0-11.6)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to explore the ability of a minimal invasive biopsy to diagnose a pathological complete response (pCR = ypT0) in the breast. METHODS: Ultrasound-guided, vacuum-assisted, minimal invasive biopsy (VAB) was performed in 50 patients after neoadjuvant chemotherapy and before breast surgery. Negative predictive values (NPV) and false negative rates (FNR) to predict a pCR in surgical specimen were the main outcome measures. To assess the possible sampling error, the representativeness of the sample was evaluated by the biopsy performing physician (subjectively based on the visibility in ultrasound), by radiography of the biopsy specimen, and by the pathologist (based on histopathology). RESULTS: The cohort (n = 50) consisted of 15 (30%) triple negative breast cancers, 13 (26%) human epidermal growth factor receptor 2 (HER2) positive and 22 (44%) hormone receptor positive/HER2 negative cancers. ypT0 was diagnosed in 23 (46%) cases. In the overall cohort (n = 50), VAB yielded an NPV of 76.7% and an FNR of 25.9%. Given a representative VAB sample, according to the histopathological evaluation (n = 38), the NPV was 94.4% (95% CI 87.1-100.0) and the FNR 4.8% (95% CI 0.0-11.6). Non-representative VABs were mainly due to bad visibility of the target lesion in ultrasound. CONCLUSION: A VAB can accurately diagnose a pCR, given a histopathologically representative sample.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Heil J, Schaefgen B, Sinn P, et al. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? Eur J Cancer. 2016. PMID: 27821317. doi:10.1016/j.ejca.2016.09.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。